Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation - PubMed
3 hours ago
- #GLP-1RA
- #Cardiovascular Risk
- #Diabetes
- Study examines the impact of discontinuing GLP-1 receptor agonists (GLP-1RAs) on major adverse cardiovascular events (MACE) in adults with type 2 diabetes.
- Target trial emulation using US Department of Veterans Affairs data from 2017 to 2023, involving 132,551 GLP-1RA users and 201,136 sulfonylurea users.
- Findings show that cardiovascular benefits of GLP-1RAs are duration-dependent, with continuous use for 2-3 years significantly reducing MACE risk.
- Discontinuation or interruption of GLP-1RA treatment progressively increases the risk of MACE, with longer discontinuation periods leading to higher risks.
- Compared to sulfonylureas, continuous GLP-1RA use for three years showed the most pronounced reduction in MACE risk (incidence risk ratio 0.82).
- Brief periods of discontinuation (0.5 years) already showed increased MACE risk, which escalated with longer discontinuation durations.